C A S T A N D B L O W N F I L M LEADING PACKAGING FILM SUPPLIER • Improve quality, limiting melt fracture and die built up • Increase productivity, reducing cleaning frequency • More sustainable manufacturing process • Regulatory compliance HIFORMER™ Liquid Polymer Processing Aid AVIENT SOLUTION • Increased processing efficiency and overall productivity with low let down ratio • Delivered significant improvement in melt fracture and die build up • Sustainability benefits provided, including possibility for longer production runs, reduced energy consumption and less waste WHY AVIENT K E Y RE Q U I RE M E N T S P R O D U C T I V I T Y + S U S TA I N A B I L I T Y LEARN MORE

ELECTRICAL APPLIANCE BRAND H O U S E H O L D P R O D U C T S I N R E C Y C L E D A B S A N D P S • Support to qualify a new raw material sourcing process • Color prediction feasibility for new material grades • Color design guidance to maintain brand identity and differentiation • Color solutions that work with mixed grades of rABS and recycled polystyrene • Worked with the brand owner to test multiple styrenic grades and understand the best fit across colors and recycled resins • Supported integration of multiple resin solutions for the best rendering and aesthetics in rABS and rPS • Helped approve 7 colors to be launched within the forthcoming 18 months PCR Color Prediction Service KEY REQUIREMENTS WHY AVIENT?

Avient corporation first quarter 2024 results and 2024 financial guidance AVIENT CORPORATION F I R S T Q U A R T E R 2 0 2 4 R E S U L T S A N D 2 0 2 4 F I N A N C I A L G U I D A N C E (NYSE: AVNT) M AY 7 , 2 0 2 4 DISCLAIMER Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For the same reasons, Avient is unable to address the probable significance of the unavailable information. 2 O P E N I N G RE MARK S 4 REGIONAL DEMAND TRENDS-TOTAL COMPANY Q 1 S A L E S V S P Y ( E X C L U D I N G F X ) 4 +2% -6% Flat +2% Avient ex. FX -1.5% FX -0.5% Total Avient -2.0% Q 1 2024 RE S U LT S Q1 2024 PERFORMANCE VS.

MEDICAL EQUIPMENT MANUFACTURER S U R G I C A L X - R A Y G L A S S E S • Replace lead while providing uniform shielding performance • Radiation shielding up to 140KeV • Improve glasses design • Compliance with Radiation Protection Regulation: Adult eye exposure must be below 20 mSv per calendar year • Conducted extensive testing to ensure comparable and uniform shielding performance • Improved geometric flexibility • Lowered shielding component costs 30-50% by eliminating machining and assembly steps (associated with lead) • Reduced weight of the glasses and enabled a more ergonomic design • Eliminated disposal concerns associated with lead Trilliant™ XR Lead Replacement Thermoplastics KEY REQUIREMENTS WHY AVIENT?

ELECTRICAL PARTS MANUFACTURER H E A V Y D U T Y C O N N E C T O R S A N D A C C E S S O R I E S • Reduce material rematching and rejection through more efficient pre-testing • Improve processing efficiencies and color consistency in highly FR-filled and high-temperature resins • Achieve regulatory compliance across multiple resin families • Gain better supply chain control to manage scarcity of key engineering resins and changing resin producers • Offered eight UL 94-recognized sites in U.S. and Canada that perform comprehensive analytical, physical and mechanical testing • Provided increased speed to market and expedited design timelines for new products using existing standardized and pre- approved color palettes • Ensured regulatory compliance and security of supply OnColor™ UL 94 Colorants KEY REQUIREMENTS WHY AVIENT AVIENT SOLUTION QUALITY + SPEED TO MARKET LEARN MORE © 2023, Avient Corporation, All Rights Reserved https://www.avient.com/products/polymer-colorants/solid-color-masterbatches/oncolor-ul94-colorants

Glucose Monitoring App Snapshot draft MEDICAL DEVICE OEM C O N T I N U O U S G L U C O S E M O N I T O R I N G S Y S T E M • Adapt to strict processing requirements of a secondary operation put in place to manufacture a new device model • Meet material size and thickness requirements while achieving desired color target • Overcome material unpredictability and sensitivity to heat, light and moisture • Minimize impact of supply chain instability and changes • Offered support for processing under low pressure conditions and at every stage of manufacturing • Performed extensive R&D work to consistently deliver the customer’s color target of a hard-to-achieve light gray • Effectively addressed all material challenges and sensitivities • Provided regular ‘summaries of understanding’ to keep up with changing forecasts and ordering patterns Mevopur™ Pre-color Formulation KEY REQUIREMENTS WHY AVIENT?

Wire & cable manufacturer WIRE & CABLE MANUFACTURER A E R O N A U T I C D A T A T R A N S M I S S I O N C A B L E S • Permanent contrast marking meeting aerospace industry standards SAE AS4373F and EN-3475-706 • Benign marking that, compared to infrared (IR) laser marking, will not damage the jacket surface • Elevated temperature performance in corrosive environments, maintaining dielectric properties under continuous service • No vital optical fiber or data transmission cable interference • Demonstrated fluorinated ethylene propylene (FEP) application expertise incorporating laser marks • Provided formulation expertise in PTFE alternatives • Delivered a high-quality product with no clumping during the extrusion process • Offered a proven array of specific aeronautic colors • Provided commercial, technical, and operational support KEY REQUIREMENTS APPEARANCE + PERFORMANCE WHY AVIENT?

MEDICAL EQUIPMENT MANUFACTURER C L O S E D S Y S T E M D R U G T R A N S F E R D E V I C E • A new material for a seal inside the next generation of closed system drug transfer device • Compliance with stringent regulatory standards: • Biocompatibility to ISO10993 • USP VI compliance • Provided regulatory support services and expertise throughout extensive medical approval process • Provided a custom formulation compliant with the highest healthcare regulatory standards • Enabled material to be manufactured and shipped globally Custom Versalloy™ HC 9220-90 Formulation KEY REQUIREMENTS WHY AVIENT?

Hanna consolidate • Cultures clash – commodity wins • Dependent on income derived from commodity joint ventures The First 6 Years • Globally organized along three strategic platforms • Non-core equity investment dispositions • Talent upgrades, discipline instilled throughout organization • New CEO hired to transform POL into specialty business �18 of 20 officers new • Implemented four pillar strategy • Nearly 50% of The Second 6 Years History of PolyOne – A Transformation • Focused on increasing volume, not profits • Heavily tied to cyclical markets 2000 2006 2012 The FormationThe Formation The TransformationThe Transformation The New PolyOneThe New PolyOne organization • Demonstrated ability to deliver • Nearly 50% of business operating income derived from Specialty Platform* • Specialty assets acquired *Pro forma for ColorMatrix acquisition Page 8 30% 50% 70% 90% $10 $12 $14 $16 $18 PolyOnePolyOne Stock Price S&P 500 (relative performance) Strategy and Execution Drive Results | | | | -50% -30% -10% 10% 30% $0 $2 $4 $6 $8 $10 2006 2007 2008 2009 2010 2011 2012 Page 9 Four Pillar Strategy The World’s Premier Provider of Specialized Polymer Materials, Services & Solutions Page 10 60% 80% 100% % o f O p ra ti g I co m * Old PolyOne Transformation 2012 Target “What We Said” Mix Shift Highlights Specialty Transformation Ahead of Schedule *Operating Income excludes Corporate Charges ** Pro Forma for the acquisition of ColorMatrix and divestiture of SunBelt 2% 34% 42% 50% >50% 0% 20% 40% 2005 2008 2011 2011** 2012 % o f O p ra ti g I co m * JV's PP&S Distribution Specialty Specialty OI $5M $46M $89M $117M “What We Said” Page 11 2007 2012 Target 2011 “Where we were” “What we said” “Where we are” 1) Operating Income % Specialty 3.2% 10% - 12% 8.9% PP&S 6.1% 8% - 10% 7.2% Pro forma ColorMatrix Proof of Performance Distribution 3.0% 4% - 5% 5.6% 2) Specialty Platform sss% of Operating Income 20% >50% 50% 3) Specialty Vitality Index 21% 35% - 40% 49% 4) ROIC* (pre-tax) 11% >15% 16% 5) Sales outside the US 37% >40% 40% *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Page 12 2011 Pro forma ColorMatrix 2015 Target “Where we are” “Where we expect to be” 1) Operating Income % Specialty 8.9% PP&S 7.2% 12 – 16% 9 – 12% Elevating our Expectations and Yours PP&S 7.2% Distribution 5.6% 2) Specialty Platform % of Operating Income 50% 3) ROIC* (after-tax) 10% 4) Adjusted Annual EPS Growth 3 yr CAGR = 71% 9 – 12% 6 – 7.5% 65 – 75% 15% Double Digit Expansion *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Page 13 • Four pillar strategy, coupled with our ability to execute is driving results • Strong leadership team driving growth & executing • Innovation and services provide differentiation and How do we get there? EPS: $2.50 Assumptions • High single digit organic revenue CAGR • Operating margins in mid range of 2015 targets • Housing starts at 85% of 50 year norm by 2015 • No investment in incremental PP&S capacity • Completion of 2-3 midsize accretive acquisitions • No divestitures • Remain comfortably below 3X Net Debt / EBITDA • No global recession 2011 Rev: $2.9B Adj.

Tyto typy korupčních obchodních aktivit se vztahují na kohokoli, s kým spolupracujeme nebo chceme spolupracovat. Naše pověst integrity je důležitější než potenciální zisky, které lze získat nepatřičným jednáním s jinými osobami a organizacemi. Obraťte se na svého právního partnera, aby vyžádal náležitou hloubkovou kontrolu a zajistil, že jste obdrželi písemný souhlas před zahájením spolupráce s jakýmkoli zástupcem nebo třetí stranou.